Nick Ruffin
I own commercial data delivery for a pharmacy-data monetization program built on NCPDP pharmacy transactions, and I manage the engineering team that builds and runs it. Retail pharmacy claims, shaped into a product that real-world evidence, market access, commercial analytics, and alt-data buyers license.
Pharmacy data, commercialized under HIPAA.
The software sits inside the pharmacy and the switch carries the claim, so the program captures the raw NCPDP transmission whole — the pharmacy's request, the routing header, the processor's response, and the adjudication itself. A dataset assembled downstream of adjudication cannot be made to look like this one, which is what makes it licensable rather than merely available.
Patient-level tokenization
Unlocks patient matching through overlap analysis against a customer's own population, then longitudinal linkage into the medical claims and lab data they already hold.
Customer-controlled AWS or Azure
Identified data landed inside customer-owned environments for buyers running their own tokenization engines — DUA-governed, HIPAA-compliant, provenance-tracked.
Cross-source combined feeds
One shared pipeline joining multiple pharmacy systems, so customers and internal teams work from a single consistent data shape.
Problems, and what each one unlocked.
Raw transmissions were a record, not a product
Shaped them into a commercial data product held to NCPDP standards, so one asset answers a different question per buyer. It runs today as a multi-year licensed portfolio that has renewed and expanded every cycle.
De-identified claims could not follow a patient
My team engineered the patient-level tokenization engine, which opened the real-world evidence and patient-journey segment: customers measure overlap against their own population before buying, then link our history to theirs.
None of it could be sold without a HIPAA determination
I run Expert Determination with third-party evaluators, which paired with the data-rights terms in our pharmacy agreements ungated commercial use across the network.
Two acquisitions left every feed inconsistent
Consolidated the platform onto one pipeline and ran the customer renewal project alongside it with business development and sales. No monetization commitment goes out without my delivery review.
Manufacturers could not see what their money bought
I own delivery of the reporting behind our copay assistance, voucher, and clinical programs, showing the abandonment at the counter a program prevented and whether the behavior it paid for changed.
Delivery could not be audited or scaled
My team rebuilt it as a governed enterprise platform: infrastructure defined as code, access controlled per customer, every transfer monitored and evidenced, and new customers onboarded as configuration rather than a build.